Dr Souphiyeh Samizadeh advises on disinfection of the skin prior to injectable treatment
Subscriber content
To read this post in full you need an Aesthetics Journal subscription. Choose the plan that fits your practice — every paid plan includes the complete peer-reviewed clinical library and CPD-accredited learning.
Already a subscriber? Log in
Medical aesthetic company Evolus Inc has announced that the European Commission (EC) has approved the marketing of Nuceiva prabotulinumtoxinA (branded Jeuveau in the US and known in other markets as Nabota).
The Aesthetic Medicine Congress (TAMC), in association with the British College of Aesthetic Medicine, will take place in Dubrovnik on October 12 and 13.
On September 9, senior leaders of pharmaceutical company Galderma UK and Ireland and aesthetic product distributor Med-fx met for the official unveiling of their partnership at the Med-fx headquarters in Witham, Essex.
High street retailer Superdrug has announced that one in five of all patients treated in the last year on its Skin Renew Service featuring botulinum toxin and filler treatments have been male, with an average age of 45-49 years.
Aesthetic training provider Harley Academy has launched a new course called the Foundation Programme for Botox and Dermal Fillers.
US-based medical aesthetic company Evolus Inc has begun a consumer campaign in the US called ‘#NEWTOX NOW’ in the hope to encourage patients to use its botulinum toxin.
On May 14, pharmaceutical company Galderma (UK) Limited celebrated 10 years since Azzalure®(AbobotulinumtoxinA) was first approved in Europe for the treatment of glabellar lines.
Pharmaceutical company Galderma (UK) Limited and aesthetic and skincare product supplier Med-fx Ltd will launch new, enhanced packages of customer-centric support services for healthcare professionals who purchase products marketed under the Azzalure and Restylane brands in the UK and Ireland from September 8.
The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.
